Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Equity Income: 2021-2023

Historic Equity Income for Intellia Therapeutics (NTLA) over the last 3 years, with Dec 2023 value amounting to -$15.6 million.

  • Intellia Therapeutics' Equity Income fell 45.57% to -$4.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$15.6 million, marking a year-over-year decrease of 41.10%. This contributed to the annual value of -$15.6 million for FY2023, which is 41.10% down from last year.
  • Intellia Therapeutics' Equity Income amounted to -$15.6 million in FY2023, which was down 41.10% from -$11.1 million recorded in FY2022.
  • Intellia Therapeutics' Equity Income's 5-year high stood at -$1.3 million during FY2021, with a 5-year trough of -$15.6 million in FY2023.
  • Its 3-year average for Equity Income is -$9.3 million, with a median of -$11.1 million in 2022.
  • Data for Intellia Therapeutics' Equity Income shows a maximum YoY slumped of 736.15% (in 2022) over the last 5 years.
  • Over the past 3 years, Intellia Therapeutics' Equity Income (Yearly) stood at -$1.3 million in 2021, then slumped by 736.15% to -$11.1 million in 2022, then crashed by 41.10% to -$15.6 million in 2023.